Publications 2011 - Team 3

  • Alanio, A., Desoubeaux, G., Sarfati, C., Hamane, S., Bergeron, A., Azoulay, E., Molina, J.M., Derouin, F., Menotti, J., 2011. Real-time PCR assay-based strategy for differentiation between active Pneumocystis jirovecii pneumonia and colonization in immunocompromised patients. Clin. Microbiol. Infect. Off. Publ. Eur. Soc. Clin. Microbiol. Infect. Dis. 17, 1531–1537.
 
  • Badin J, Boulain T, Ehrmann S, Skarzynski M, Bretagnol A, Buret J, Benzekri-Lefevre D, Mercier E, Runge I, Garot D, Mathonnet A, Dequin PF, Perrotin D. Relation between mean arterial pressure and renal function in the early phase of shock: a prospective, explorative cohort study. Crit Care. 2011;15(3):R135.
 
  • Belze O Jr, Legras A, Ehrmann S, Garot D, Perrotin D. Cannabis-induced acute pancreatitis. Am J Emerg Med. 2011 Jan;29(1):131.e3-4. 
 
  • Burke CW, Mason JN, Surman SL, Jones BG, Dalloneau E, Hurwitz JL, Russell CJ. Illumination of parainfluenza virus infection and transmission in living animals reveals a tissue-specific dichotomy. PLoS Pathog. 2011 Jul;7(7):e1002134. 
 
  • Carmier D, Diot E, Diot P. Shrinking lung syndrome: recognition, pathophysiology and therapeutic strategy. Expert Rev Respir Med. 2011 Feb;5(1):33-9. 
 
  • Coates AL, Leung K, Vecellio L, Schuh S. Testing of nebulizers for delivering magnesium sulfate to pediatric asthma patients in the emergency department. Respir Care. 2011 Mar;56(3):314-8. 
 
  • Dalloneau E, Pereira PL, Brault V, Nabel EG, Hérault Y.Prmt2 regulates the lipopolysaccharide-induced responses in lungs and macrophages. J Immunol. 2011 Nov 1;187(9):4826-34. 
 
  • Diot E, Carmier D, Marquette D, Marchand-Adam S, Diot P, Lesire V.IV immunoglobulin might be considered as a first-line treatment of severe interstitial lung disease associated with polymyositis. Chest. 2011 Aug;140(2):562-3.
 
  • Durand M., Pourchez J., Aubert G., Le Guellec S., Navarro L., Forest V., rusch P., Cottier M. Impact of acoustic airflow nebulization on intrasinus drug deposition of a human plastinated nasal cast: New insights into the mechanisms involved. Int J Pharm, 2011, Dec 12;421(1):63-71.
 
  • Garot D, Respaud R, Lanotte P, Simon N, Mercier E, Ehrmann S, Perrotin D, Dequin PF, Le Guellec C. Population pharmacokinetics of ceftriaxone in critically ill septic patients: a reappraisal. Br J Clin Pharmacol. 2011 Nov;72(5):758-67. 
 
  • Gaud G, Iochmann S, Guillon-Munos A, Brillet B, Petiot S, Seigneuret F, Touzé A, Heuzé-Vourc'h N, Courty Y, Lerondel S, Gruel Y, Reverdiau P. TFPI-2 silencing increases tumour progression and promotes metalloproteinase 1 and 3 induction through tumour-stromal cell interactions. J Cell Mol Med. 2011 Feb;15(2):196-208. 
 
  • Guilleminault L, Carré P, Beau-Salinas F, Taillé C, Dieudé P, Crestani B, Diot P, Marchand-Adam S. Asthma unmasked with tumor necrosis factor-α-blocking drugs. Chest. 2011 Oct;140(4):1068-71. 
 
  • Guillon A, Montharu J, Cormier B, Vecellio L, Diot P, de Monte M. New insights into the pathophysiology of aspiration pneumonia. Br J Anaesth. 2011 Apr;106(4):608-9 
 
  • Guillon-Munos A, Oikonomopoulou K, Michel N, Smith CR, Petit-Courty A, Canepa S, Reverdiau P, Heuzé-Vourc'h N, Diamandis EP, Courty Y. Kallikrein-related peptidase 12 hydrolyzes matricellular proteins of the CCN family and modifies interactions of CCN1 and CCN5 with growth factors. J Biol Chem. 2011. 286(29):25505-18. 
 
  • Lakhal K, Ehrmann S, Benzekri-Lefèvre D, Runge I, Legras A, Dequin PF, Mercier E, Wolff M, Régnier B, Boulain T.Respiratory pulse pressure variation fails to predict fluid responsiveness in acute respiratory distress syndrome. Crit Care. 2011;15(2):R85.
 
  • Lakhal K, Ehrmann S, Chaari A, Laissy JP, Régnier B, Wolff M, Pajot O. Acute Kidney Injury Network definition of contrast-induced nephropathy in the critically ill: incidence and outcome. J Crit Care. 2011 Dec;26(6):593-9.
 
  • Laube BL, Janssens HM, de Jongh FH, Devadason SG, Dhand R, Diot P, Everard ML, Horvath I, Navalesi P, Voshaar T, Chrystyn H; European Respiratory Society; International Society for Aerosols in Medicine. What the pulmonary specialist should know about the new inhalation therapies. Eur Respir J. 2011 Jun;37(6):1308-31. 
 
  • Lemarie E, Vecellio L, Hureaux J, Prunier C, Valat C, Grimbert D, Boidron-Celle M, Giraudeau B, le Pape A, Pichon E, Diot P, el Houfia A, Gagnadoux F.Aerosolized gemcitabine in patients with carcinoma of the lung: feasibility and safety study. J Aerosol Med Pulm Drug Deliv. 2011 Dec;24(6):261-70. 
 
  • Maillet A, Guilleminault L, Lemarié E, Lerondel S, Azzopardi N, Montharu J, Congy-Jolivet N, Reverdiau P, Legrain B, Parent C, Douvin DH, Hureaux J, Courty Y, De Monte M, Diot P, Paintaud G, Le Pape A, Watier H, Heuzé-Vourc'h N. The Airways, a Novel Route for Delivering Monoclonal Antibodies to Treat Lung Tumors. Pharm Res. 2011. 28(9):2147-56 
 
  • Vecellio L., De Gersem R., Le Guellec S., Reychler G., Pitance L., Le Pennec D., Diot P., Chantrel G., Bonfils P., Jamar F., Deposition of aerosols delivered by nasal route with jet and mesh nebulizers. Int J Pharm, 2011, Apr 4;407(1-2):87-94.
 
  • Vecellio L, Abdelrahim ME, Montharu J, Galle J, Diot P, Dubus JC. Disposable versus reusable jet nebulizers for cystic fibrosis treatment with tobramycin. J Cyst Fibros. 2011 Mar;10(2):86-92